ImmunoGen Performance
| IMGNDelisted Stock | USD 31.23 0.01 0.03% |
On a scale of 0 to 100, ImmunoGen holds a performance score of 21. The company retains a Market Volatility (i.e., Beta) of -4.51, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ImmunoGen are expected to decrease by larger amounts. On the other hand, during market turmoil, ImmunoGen is expected to outperform it. Please check ImmunoGen's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether ImmunoGen's current trending patterns will revert.
Risk-Adjusted Performance
21 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in ImmunoGen are ranked lower than 21 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting technical and fundamental indicators, ImmunoGen displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 309.5 M |
ImmunoGen |
ImmunoGen Relative Risk vs. Return Landscape
If you would invest 2,957 in ImmunoGen on January 26, 2024 and sell it today you would earn a total of 166.00 from holding ImmunoGen or generate 5.61% return on investment over 90 days. ImmunoGen is currently generating 0.4685% in daily expected returns and assumes 1.6705% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than ImmunoGen, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ImmunoGen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmunoGen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ImmunoGen, and traders can use it to determine the average amount a ImmunoGen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2805
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.67 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.47 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.28 actual daily | 21 79% of assets perform better |
Based on monthly moving average ImmunoGen is performing at about 21% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImmunoGen by adding it to a well-diversified portfolio.
ImmunoGen Fundamentals Growth
ImmunoGen Stock prices reflect investors' perceptions of the future prospects and financial health of ImmunoGen, and ImmunoGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmunoGen Stock performance.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Price To Earning | (4.49) X | |||
| Price To Book | 15.53 X | |||
| Price To Sales | 30.33 X | |||
| Revenue | 287.61 M | |||
| EBITDA | (78.46 M) | |||
| Cash And Equivalents | 373.87 M | |||
| Cash Per Share | 1.69 X | |||
| Total Debt | 15.24 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 2.06 X | |||
| Cash Flow From Operations | (197.89 M) | |||
| Earnings Per Share | (0.28) X | |||
| Total Asset | 348.94 M | |||
| Retained Earnings | (1.69 B) | |||
| Current Asset | 253.11 M | |||
| Current Liabilities | 60.44 M | |||
About ImmunoGen Performance
To evaluate ImmunoGen Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when ImmunoGen generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare ImmunoGen Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand ImmunoGen market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents ImmunoGen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.Things to note about ImmunoGen performance evaluation
Checking the ongoing alerts about ImmunoGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImmunoGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmunoGen is not yet fully synchronised with the market data | |
| ImmunoGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 287.61 M. Net Loss for the year was (73.52 M) with loss before overhead, payroll, taxes, and interest of (104.76 M). | |
| ImmunoGen currently holds about 373.87 M in cash with (197.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.69. | |
| Over 91.0% of the company shares are owned by institutional investors |
- Analyzing ImmunoGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmunoGen's stock is overvalued or undervalued compared to its peers.
- Examining ImmunoGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmunoGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmunoGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmunoGen's stock. These opinions can provide insight into ImmunoGen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the ImmunoGen information on this page should be used as a complementary analysis to other ImmunoGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |